{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:47:58Z","timestamp":1785797278803,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A substantial proportion of individuals with palindromic rheumatism develop rheumatoid arthritis (RA). This randomized, open-label, multicenter trial aimed to assess whether 2 years of treatment with abatacept (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200934; 125\u2009mg subcutaneous injections weekly during the first year and every 2 weeks during the second year) compared with oral hydroxychloroquine (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200936; 5\u2009mg kg\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>1<\/jats:sup>\n                    per day) could reduce the frequency of RA development in individuals with palindromic rheumatism positive for rheumatoid factor and\/or anticitrullinated protein antibody. The primary outcome was the development of persistent arthritis that fulfilled the 2010 RA classification criteria of the American College of Rheumatology and the European Alliance of Associations for Rheumatology, as evaluated by the participant clinicians during the 24 months of follow-up. Secondary outcomes included the frequency, intensity and duration of joint attacks, the proportion of patients in remission and the frequency of adverse events. In the primary analysis, in the modified full analysis set with failure imputation, 7 (20.6%) of the 34 participants treated with abatacept and 18 (50.0%) of the 36 participants treated with hydroxychloroquine developed RA during the 24 months of follow-up (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.010; risk difference 29.4%, 95% confidence interval 8.2 to 50.7), meeting the primary endpoint. Using the available-data-only approach, the corresponding figures were 3 (10.0%) of 30 individuals and 10 (35.7%) of 28 individuals, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.019). Compared with participants treated with hydroxychloroquine, participants treated with abatacept had a significantly longer time to progression to RA (hazard ratio 0.27, 95% confidence interval 0.07 to 0.96; log-rank test\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0299). Abatacept was also associated with a reduced intensity of joint attacks and a higher frequency of symptom remission; however, there were no differences in the frequency of attacks between the two study drugs. No relevant differences in the evolution of antimodified peptide and\/or protein antibody titers were observed between the two treatment arms. Both drugs were well tolerated. In patients with seropositive palindromic rheumatism, compared with hydroxychloroquine, abatacept given for 2 years reduced the risk of progression to RA and improved symptoms. ClinicalTrials.gov identifier\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03669367\" ext-link-type=\"uri\">NCT03669367<\/jats:ext-link>\n                    and EudraCT no. 2017-004543-20.\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04395-6","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:04:20Z","timestamp":1778749460000},"page":"2610-2618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-3806","authenticated-orcid":false,"given":"Raimon","family":"Sanmarti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"de-Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Escudero-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Graell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Kanterewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e8ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-6557","authenticated-orcid":false,"given":"Irati","family":"Urionaguena-Onaindia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"L\u00f3pez-Lasanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Sala-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-8434","authenticated-orcid":false,"given":"Beatriz","family":"Frade-Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Morl\u00e0-Novell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Polino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Meraz-Ostiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Oreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inma","family":"P\u00e9rez-Nadales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Ortega-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Busquets-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Domingo","family":"G\u00f3mez-Centeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Rodr\u00edguez-Cros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Milena","family":"Millan-Arciniegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Francisco","family":"Garc\u00eda-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9161-3886","authenticated-orcid":false,"given":"Helena","family":"Borrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gueda","family":"Prior-Espa\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Castell-Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cruceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Bonfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Domenech-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Roca-F\u00e0bregas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-8784","authenticated-orcid":false,"given":"Jos\u00e9","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Tobalina-Maestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-4833","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"G\u00f3mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-2340","authenticated-orcid":false,"given":"Isabel","family":"Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"4395_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41584-019-0308-5","volume":"15","author":"K Mankia","year":"2019","unstructured":"Mankia, K. & Emery, P. Palindromic rheumatism as part of the rheumatoid arthritis continuum. Nat. Rev. Rheumatol. 15, 687\u2013695 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4395_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.657983","volume":"8","author":"R Sanmarti","year":"2021","unstructured":"Sanmarti, R. et al. Palindromic rheumatism: just a pre-rheumatoid stage or something else? Front. Med. (Lausanne) 8, 657983 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"4395_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/ard-2023-224211","volume":"84","author":"KD Deane","year":"2025","unstructured":"Deane, K. D. et al. Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease. Ann. Rheum. Dis. 84, 14\u201328 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"4395_CR4","first-page":"1240","volume":"33","author":"AS Russell","year":"2006","unstructured":"Russell, A. S., Devani, A. & Maksymowych, W. P. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J. Rheumatol. 33, 1240\u20131242 (2006).","journal-title":"J. Rheumatol."},{"key":"4395_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.39603","volume":"68","author":"K Mankia","year":"2016","unstructured":"Mankia, K. & Emery, P. Preclinical rheumatoid arthritis: progress toward prevention. Arthritis Rheumatol. 68, 779\u2013788 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"4395_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","volume":"78","author":"DM Gerlag","year":"2019","unstructured":"Gerlag, D. M. et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann. Rheum. Dis. 78, 179\u2013185 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"4395_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","volume":"403","author":"J Rech","year":"2024","unstructured":"Rech, J. et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 403, 850\u2013859 (2024).","journal-title":"Lancet"},{"key":"4395_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope, A. P. et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403, 838\u2013849 (2024).","journal-title":"Lancet"},{"key":"4395_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.semarthrit.2020.11.008","volume":"51","author":"D Corradini","year":"2021","unstructured":"Corradini, D., Di Matteo, A., Emery, P. & Mankia, K. How should we treat palindromic rheumatism? A systematic literature review. Semin. Arthritis Rheum. 51, 266\u2013277 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"4395_CR10","first-page":"41","volume":"27","author":"L Gonzalez-Lopez","year":"2000","unstructured":"Gonzalez-Lopez, L., Gamez-Nava, J. I., Jhangri, G., Russell, A. S. & Suarez-Almazor, M. E. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J. Rheumatol. 27, 41\u201346 (2000).","journal-title":"J. Rheumatol."},{"key":"4395_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","volume":"15","author":"M Pombo-Suarez","year":"2019","unstructured":"Pombo-Suarez, M. & Gomez-Reino, J. J. Abatacept for the treatment of rheumatoid arthritis. Expert. Rev. Clin. Immunol. 15, 319\u2013326 (2019).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"4395_CR12","first-page":"455","volume":"38","author":"E Alemao","year":"2020","unstructured":"Alemao, E., Postema, R., Elbez, Y., Mamane, C. & Finckh, A. Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis. Clin. Exp. Rheumatol. 38, 455\u2013466 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"4395_CR13","first-page":"35","volume":"18","author":"W Youssef","year":"1991","unstructured":"Youssef, W., Yan, A. & Russell, A. S. Palindromic rheumatism: a response to chloroquine. J. Rheumatol. 18, 35\u201337 (1991).","journal-title":"J. Rheumatol."},{"key":"4395_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/1756-185X.14302","volume":"25","author":"A Ghassembaglou","year":"2022","unstructured":"Ghassembaglou, A., Esalatmanesh, K., Gadakchi, L., Nourmohammadi, F. & Khabbazi, A. Long-term outcome of patients with palindromic rheumatism treated with methotrexate. Int. J. Rheum. Dis. 25, 489\u2013495 (2022).","journal-title":"Int. J. Rheum. Dis."},{"key":"4395_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5152\/eurjrheum.2021.20062","volume":"8","author":"P Padhan","year":"2021","unstructured":"Padhan, P. & Thakur, B. Effect of low dose methotrexate as an add-on therapy in patients with palindromic rheumatism unresponsive to hydroxychloroquine: an observational study. Eur. J. Rheumatol. 8, 130\u2013132 (2021).","journal-title":"Eur. J. Rheumatol."},{"key":"4395_CR16","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s10067-019-04578-2","volume":"38","author":"P Raghavan","year":"2019","unstructured":"Raghavan, P., Sreenath, S., Cherian, S. & Shenoy, P. D. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature. Clin. Rheumatol. 38, 2399\u20132402 (2019).","journal-title":"Clin. Rheumatol."},{"key":"4395_CR17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/art.38687","volume":"66","author":"R Alten","year":"2014","unstructured":"Alten, R. et al. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol. 66, 1987\u20131997 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"4395_CR18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3899\/jrheum.170344","volume":"45","author":"MC Genovese","year":"2018","unstructured":"Genovese, M. C. et al. Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial. J. Rheumatol. 45, 1085\u20131092 (2018).","journal-title":"J. Rheumatol."},{"key":"4395_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41927-018-0038-3","volume":"2","author":"G Simons","year":"2018","unstructured":"Simons, G. et al. Perceptions of first-degree relatives of patients with rheumatoid arthritis about lifestyle modifications and pharmacological interventions to reduce the risk of rheumatoid arthritis development: a qualitative interview study. BMC Rheumatol. 2, 31 (2018).","journal-title":"BMC Rheumatol."},{"key":"4395_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40265-024-02061-0","volume":"84","author":"T Toyoda","year":"2024","unstructured":"Toyoda, T. & Mankia, K. Prevention of rheumatoid arthritis in at-risk individuals: current status and future prospects. Drugs 84, 895\u2013907 (2024).","journal-title":"Drugs"},{"key":"4395_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","volume":"400","author":"DI Krijbolder","year":"2022","unstructured":"Krijbolder, D. I. et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet 400, 283\u2013294 (2022).","journal-title":"Lancet"},{"key":"4395_CR22","unstructured":"Deane, K. et al. Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial [abstract]. Arthritis Rheumatol. 74, abstr. 1064 (2022)."},{"key":"4395_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14740338.2025.2505542","volume":"25","author":"QY Su","year":"2026","unstructured":"Su, Q. Y. et al. Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis. Expert. Opin. Drug Saf. 25, 59\u201370 (2026).","journal-title":"Expert. Opin. Drug Saf."},{"key":"4395_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrrheum.2011.204","volume":"8","author":"A Willemze","year":"2012","unstructured":"Willemze, A., Trouw, L. A., Toes, R. E. & Huizinga, T. W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144\u2013152 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4395_CR25","unstructured":"Huizinga, T. W. J. et al. The impact on anti-citrullinated protein antibody isotypes and epitope fine specificity in patients with early RA treated with abatacept and methotrexate. In Abstracts of the 2014 ACR\/ARHP Annual Meeting Abstract 1515 (American College of Rheumatology, 2014)."},{"key":"4395_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-017-1329-6","volume":"19","author":"S Cabrera-Villalba","year":"2017","unstructured":"Cabrera-Villalba, S. et al. Differing specificities and isotypes of anti-citrullinated peptide\/protein antibodies in palindromic rheumatism and rheumatoid arthritis. Arthritis Res. Ther. 19, 141 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"4395_CR27","doi-asserted-by":"publisher","first-page":"1759720X2097813","DOI":"10.1177\/1759720X20978139","volume":"12","author":"R Castellanos-Moreira","year":"2020","unstructured":"Castellanos-Moreira, R. et al. Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 12, 1759720X20978139 (2020).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"4395_CR28","doi-asserted-by":"publisher","first-page":"eadt7214","DOI":"10.1126\/scitranslmed.adt7214","volume":"17","author":"Z He","year":"2025","unstructured":"He, Z. et al. Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation. Sci. Transl. Med. 17, eadt7214 (2025).","journal-title":"Sci. Transl. Med."},{"key":"4395_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41584-025-01342-6","volume":"22","author":"CA Hitchon","year":"2026","unstructured":"Hitchon, C. A. & El-Gabalawy, H. S. Advances in understanding preclinical rheumatoid arthritis and prospects for prevention. Nat. Rev. Rheumatol. 22, 82\u201383 (2026).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4395_CR30","doi-asserted-by":"publisher","first-page":"l6802","DOI":"10.1136\/bmj.l6802","volume":"368","author":"H Moustgaard","year":"2020","unstructured":"Moustgaard, H. et al. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. Brit. Med. J. 368, l6802 (2020).","journal-title":"Brit. Med. J."},{"key":"4395_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0895-4356(99)00139-0","volume":"53","author":"AJ Vickers","year":"2000","unstructured":"Vickers, A. J. & de Craen, A. J. Why use placebos in clinical trials? A narrative review of the methodological literature. J. Clin. Epidemiol. 53, 157\u2013161 (2000).","journal-title":"J. Clin. Epidemiol."},{"key":"4395_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2018-214175","volume":"78","author":"K Mankia","year":"2019","unstructured":"Mankia, K. et al. Identification of a distinct imaging phenotype may improve the management of palindromic rheumatism. Ann. Rheum. Dis. 78, 43\u201350 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"4395_CR33","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1136\/annrheumdis-2018-214832","volume":"79","author":"R Sanmarti","year":"2020","unstructured":"Sanmarti, R. et al. Ultrasound findings in palindromic rheumatism. Ann. Rheum. Dis. 79, e30 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"4395_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0002-9343(92)90177-D","volume":"93","author":"PA Guerne","year":"1992","unstructured":"Guerne, P. A. & Weisman, M. H. Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. Am. J. Med. 93, 451\u2013460 (1992).","journal-title":"Am. J. Med."},{"key":"4395_CR35","unstructured":"Adjustment for baseline covariates in clinical trials \u2013 Scientific guideline. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/adjustment-baseline-covariates-clinical-trials-scientific-guideline (2015)."},{"key":"4395_CR36","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3899\/jrheum.090025","volume":"36","author":"E Koskinen","year":"2009","unstructured":"Koskinen, E., Hannonen, P. & Sokka, T. Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84. J. Rheumatol. 36, 1873\u20131875 (2009).","journal-title":"J. Rheumatol."},{"key":"4395_CR37","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580\u20131588 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"4395_CR38","unstructured":"nQuery version 9. Advisor user\u2019s guide. Statistical Solutions Ltd http:\/\/www.statsols.com\/nquery-sample-size-and-power-calculation-for-successful-clinical-trials"},{"key":"4395_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/009286150804200402","volume":"42","author":"CH Mallinckrodt","year":"2008","unstructured":"Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y. & Mancuso, J. P. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf. J. 42, 303\u2013319 (2008).","journal-title":"Drug Inf. J."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04395-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:01:48Z","timestamp":1784210508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4395"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04395-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S. received consulting fees and\/or honoraria from AbbVie, BMS, Eli Lilly and Company, Gebro, MSD, Pfizer, Roche and Sanofi; participated on a Data Safety Monitoring Board or Advisory Board for AbbVie, Eli Lilly and Company, MSD, Pfizer and Sanofi; and has received educational grants from AbbVie, Pfizer and BMS. C.P.-G. has been an advisory board member for Alfa Signa lab; has received speaker honorariums from AbbVie, Lilly and Alga Sigma; and has received research grants to institution from Societat Catalana Reumatologia and Sociedad Espa\u00f1ola de Reumatolog\u00eda. G.S. received speaker honorariums from AbbVie, BMS, Eli Lilly and Company, Alpha sigma and Pfizer, and has received advisory honoraria from AbbVie and MSD. A.E.-C. has been an advisory board member or has received speaker honoraria from BMS, AbbVie, Lilly and Pfizer. M.L.-L. has been an advisory board member for AbbVie and Galapagos; and has received speaker honoraria from AbbVie, Galapagos, Pfizer, MSD and UCB. B.F.-S. has received speaker honoraria from AbbVie, GSK, AstraZeneca, Novartis, MSD, Galapagos and BMS; and has received travel grants from Lilly, Pfizer, GSK and AbbVie Galapagos. F.J.B. reports payment to the institution from Gedeon Richter Plc., Bristol Myers Squibb International corporation (BMSIC), Sun Pharma Global FZE, Celgene Corporation, Janssen Cilag International N.V, Janssen Research & Development, Viela Bio, Inc., AstraZeneca AB, UCB BIOSCIENCES GMBH, UCB BIOPHARMA SPRL, AbbVie Deutschland GmbH & Co.KG, Merck KGaA, Amgen, Inc., Novartis Farmac\u00e9utica, S.A., Boehringer Ingelheim Espa\u00f1a, S.A, CSL Behring, LLC, GlaxoSmithKline Research & Development Limited, Pfizer Inc, Lilly S.A., Corbus Pharmaceuticals Inc., Biohope Scientific Solutions for Human Health S.L., Centrexion Therapeutics Corp., Sanofi, MEIJI FARMA S.A., Kiniksa Pharmaceuticals, Ltd, Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Del Hospital Cl\u00ednico San Carlos, Gr\u00fcnenthal and Galapagos. I.P.-N. received speaker honoraria from UCB and Novartis. R.O.-C. has received speaker honoraria from BMS, AbbVie, Lilly and Pfizer. A.D.G.-C. has been an advisory board member for Sanofi and Lilly; has received speaker honoraria from Sanofi, Lilly, Pfizer, UCB and Vifor; has received a consulting honorarium from Sanofi; has received advisory honoraria from Sanofi, Lilly, Pfizer, UCB and AbbVie; and has received travel grants from Sanofi, AbbVie, Pfizer and UCB. J.F.G.-L. has received speaker honoraria from AbbVie, Lilly, Gebro, Gr\u00fcnenthal and Novartis; has received research grants to institution from Novartis and Gal\u00e1pagos; and has received travel grants from Nordic, Gebro, Rovi, AbbVie, Lilly, AstraZeneca, UCB and Jansen. S.C.-Q. has received speaker honoraria from Janssen, AbbVie, Lilly, Novartis, UCB and Theramex. J.R. reports educational and scientific outreach lectures from Novartis, Chiesi, Novo Nordisk, Sanofi Aventis, Boehringer Ingelheim, Lilly, Vifor-Fresenius and Gr\u00fcnenthal; and DSMB fees from CZ Vaccines, all outside the submitted work. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}